Aiko Sugiyama

Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide

Takayuki Goto, S. Akamatsu, Yoshifumi Miyawaki, 2023, Cancer science.